文献速递胸部肿瘤放疗

日本可手术Ⅰ期非小细胞肺癌立体定向体部放疗与手术的成本效用分析

Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage I Non-small Cell Lung Cancer in Japan.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-09-29

该研究构建分区生存模型,比较日本可手术Ⅰ期非小细胞肺癌患者接受立体定向体部放疗(SBRT)与手术的终身成本与结局。SBRT组数据来自纳入678例可手术Ⅰ期NSCLC患者的多中心队列,手术组采用注册数据,时间跨度10年。SBRT为优势策略,较手术降低治疗成本4443.8美元并增加0.131个质量调整生命年。

要点

  • SBRT较手术降低治疗成本4443.8美元并增加0.131个质量调整生命年,为优势策略。
  • 概率敏感性分析中SBRT为优势策略和具成本效用的概率分别为50.6%和72.4%。
  • 预算影响分析显示日本Ⅰ期NSCLC患者(n=1407)总节省6252870.0美元。

核心结论

  • 在日本可手术Ⅰ期非小细胞肺癌患者中,SBRT是较手术更具成本效用的选择。

研究设计与样本

  • 采用分区生存模型,SBRT组数据来自纳入678例可手术Ⅰ期NSCLC患者的日本多中心队列研究,手术组采用患者注册数据。
  • 模型使用各治疗组的总生存和无进展生存数据,时间跨度设为10年,成本和效用值来自国内及海外文献。

主要发现

  • 5年总生存率SBRT组为78.2%,手术组为74.8%。
  • 5年无进展生存率SBRT组为57.0%,手术组为63.4%。
  • SBRT较手术降低治疗成本4443.8美元并增加0.131个质量调整生命年。
  • 概率敏感性分析中SBRT为优势策略的概率为50.6%,具成本效用的概率为72.4%。
  • 预算影响分析显示日本Ⅰ期NSCLC患者(n=1407)总节省6252870.0美元。

关键数值与推荐

  • 无进展生存状态效用值为0.74,疾病进展状态效用值为0.65,来自国内和海外文献。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要反映最新临床现实(如总生存/无进展生存)的大规模流行病学研究来验证本研究的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) for patients with operable stage I non-small cell lung cancer (NSCLC) is less invasive than surgery. However, differences in lifetime costs and patient outcomes remain unclear. In this study, a cost-utility analysis of SBRT compared with surgery for Japanese patients with operable stage I NSCLC was conducted. METHODS AND MATERIALS: A partitioned survival model was constructed using each treatment arm's overall survival (OS) and progression-free survival (PFS) data. The data for the SBRT arm were extracted from the Japanese multicenter cohort study, which enrolled 678 medically operable patients with stage I NSCLC, and patient registry data were used for the surgery arm. The 5-year OS rate was 78.2% for SBRT and 74.8% for surgery from both studies. The 5-year PFS rate was 57.0% for SBRT and 63.4% for surgery. The quality of life values of PFS and progressive disease were obtained from domestic and overseas literature (PFS: 0.74, progressive disease: 0.65). The time horizon was set to 10 years. The expected costs and quality-adjusted life years for each treatment group were calculated. All costs are expressed in Japanese yen converted to US dollars (USD). RESULTS: SBRT was the dominant strategy, reducing treatment costs by 4,443.8 USD and increasing quality-adjusted life years by 0.131 compared with surgery. According to probabilistic sensitivity analysis, the probability of SBRT being dominant and cost-effective was 50.6% and 72.4%, respectively. Under the budget impact analysis, the total savings for the patients with stage I NSCLC in Japan was 6,252,870.0 USD (n = 1,407). CONCLUSIONS: SBRT is a more cost-effective option than surgery in patients with medically operable stage I NSCLC in Japan. Large-scale epidemiologic studies that reflect the latest clinical realities, such as OS/PFS, will be needed to validate this study's robustness.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Igarashi A, Onishi H, Shioyama Y, et al. Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage I Non-small Cell Lung Cancer in Japan. Int J Radiat Oncol Biol Phys. 2024. PMID: 39352324. doi:10.1016/j.ijrobp.2024.07.2328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。